Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dainippon Sumitomo To Conduct Trials Outside Japan

This article was originally published in PharmAsia News

Executive Summary

Japan's Dainippon Sumitomo Pharma became the latest drug maker to announce it would shift some of its clinical trials to other Asian nations. Dainippon said that among the drugs being developed for the Japanese market is its antipsychotic treatment lurasidone, which is to undergo Phase III tests in South Korea and Taiwan. The move was made possible after Japan's health ministry indicated it would acknowledge foreign trials if they include at least some Japanese patients. Dainippon said future trials abroad would be held in areas where the people are similar physically to Japanese. (Click here for more - a subscription may be required
UsernamePublicRestriction

Register

SC068614

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel